Study on expression of CDH4 in lung cancer by Zhupeng Li et al.
RESEARCH Open Access
Study on expression of CDH4 in lung
cancer
Zhupeng Li1, Dan Su2, Lisha Ying2, Guangmao Yu1 and Weimin Mao3*
Abstract
Background: The human CDH4 gene, which encodes the R-cadherin protein, has an important role in cell
migration and cell adhesion, sorting, tissue morphogenesis, and tumor genesis. This study analyzed the
relationship of CDH4 mRNA expression with lung cancer.
Methods: Real time PCR was applied to detect CDH4 mRNA transcription in 142 paired cases of lung cancer
and noncancerous regions.
Results: No correlation was identified between CDH4 mRNA expression and gender, age, lymphnode
metastasis, TNM stage, family history, smoking state, drinking state (P > 0.05), but grade and histotype
(P < 0.05). The relative CDH4 mRNA value was remarkably decreased in lung cancer tissues compared with
noncancerous tissues (P = 0.001).
Conclusions: We found that CDH4 mRNA expression was associated with grade and histotype. What is more,
the relative CDH4 mRNA value was decreased in the lung cancer tissues. Our results suggested that CDH4
might be a putative tumor suppressor gene (TSG) in lung cancer.
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Background
Lung cancer has the highest morbidity and mortality in
malignant tumors and with a total of 1.5 million deaths
annually worldwide [1]. In the patients with lung cancer,
though diagnosis and treatment have been greatly
advanced, the 5-year survival rate remains low [2, 3].
Many etiological factors correlate with lung cancer, for
example, genetic susceptibility, environmental factors,
smoking, and so on, but the mechanism of lung cancer
development and progression is yet unclear.
Cadherins are transmembrane adhesion, calcium-
dependent molecules, which have a lot of functions, for
instance, cell signaling, cell–cell cohesion, and inhibition
of apoptosis [4]. Cadherins regulate cell growth, mobil-
ity, and differentiation by binding through the cytoplas-
mic domain to b-catenin or c-catenin [5]. More than
100 cadherins have been found with diverse protein
structures.
R-cadherin is a classic cadherin, which is important
for the differentiation of kidney, striated muscle, brain,
and so on [6, 7]. R-cadherin plays a critical role in main-
taining cell polarity and tissue architecture in normal
gastrointestinal epithelial tissue [8].
The human CDH4 gene encodes the R-cadherin
protein, which is located on chromosome 20q13.3 [9].
Previous reports have showed that R-cadherin is in-
volved in cell migration, cell adhesion, sorting, tissue
morphogenesis, and tumorgenesis. CDH4 might be a
tumor suppressor gene in various cancers, such as naso-
pharyngeal carcinoma, gastric cancer, and colorectal
cancer [10–12]. However, the CDH4 expression in lung
cancer and its’ correlation with lung cancer clinical char-
acteristics were still unclear.
In this study, we first investigated the transcription
levels of CDH4 mRNA in lung cancer tissues and paired
noncancerous regions, to explore the relationship be-
tween CDH4 mRNA and clinical characteristics, and
attempted to illustrate that CDH4 was a tumor suppres-
sor gene (TSG) in lung cancer.* Correspondence: mwm1218@126.com3Department of Thoracic Surgery, Zhejiang Cancer Hospital, 38 Guangji Road,
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We collected 142 pair cases of fresh carcinoma and
normal tissues from patients with lung cancer, all of
them underwent surgery in Zhejiang Cancer Hospital
from May 2012 to May 2013. Normal tissues were ob-
tained as far (at least 5 cm) from the tumor tissue as
possible. We froze the samples in liquid nitrogen and
stored them at −80 °C as soon as possible. All of the pa-
tients did not receive preoperative radiochemotherapy.
Patient clinical characteristics are summarized in Table 1.
The classification criteria of International Association
for the Study of Lung Cancer and the World Health
Organization (IASLC/WHO) were used for histodiagno-
sis [13]. The TNM stage of the disease was determined
by the new IASLC staging methods [14]. Our research
was approved by Zhejiang Cancer Hospital Ethics Com-
mittee. Informed consents were provided for all patients
before surgery.
Reverse transcription PCR
We extracted total RNA in tissues with Trizol kit
((Invitrogen, USA). The quality and concentration of
RNA were evaluated by spectrophotometer. RT-PCR
was conducted with One Step SYBR® Ex Taq™ qRT-PCR
Kit (Takara, Japanese). The RT-PCR reaction was con-
ducted in a 25-μl volume, containing TaKaRa Ex Taq HS
(5 U/μl), 0.5 μl; PCR Forward Primer (10 μM), 0.5 μl;
RTase Enzyme Mix, 0.5 μl; total RNA, 2 μl; PCR Reverse
Primer (10 μM), 0.5 μl; RNase Free dH2O, 8.5 μl; 2 ×
One Step SYBR® RT-PCR Buffer, 12.5 μl. Amplification
reactions were carried out as follows: stage 1: reverse
transcription hold: 42 °C for 5 min, 95 °C for 10 s; stage
2: PCR reaction repeat: 40 cycles of 95 °C for 5 s, 60 °C
for 20 s; stage 3: melt curve. The amplification reactions
of the GAPDH were performed in the same tube. The
GenBank sequences were used to design CDH4 and
GAPDH primer sets. CDH4 reverse primer, 5′-GAA
GACCAGCAGGGAGTCATAG-3′, CDH4 forward pri-
mer, 5′-CACCAAAAACAACGTCTACGAG-3′; GAPDH
reverse primer, 5′-GAAGATGGTGATGGGATTTC-3′,
GAPDH forward primer, 5′-GAAGGTGAAGGTCG-
GAGTC′. The ABI step-one plus performed the quantita-
tive real-time PCR testing. Ct value was calculated with
SDS2.1 software. GAPDH was used as a reference gene,
when detected the relative expression of CDH4 mRNA.
We used the 2−△△Ct method to calculate the relative quan-
tity (RQ) value.
Statistical analysis
The obtained results were not normal distribution value
(P < 0.05), analyzed by the Komlogorov-Smirnov test. So,
analyses of the CDH4 mRNA relative value between the
different groups were carried out by the Kruskall–Wallis
test. The correlation between relative CDH4 mRNA
value and clinical characteristics was estimated with the
Spearman test. SPSS17.0 software was used for all statis-
tical analyses. Bilateral test P < 0.05 was considered to
have statistical significance.
Table 1 The correlation between clinical characteristics and
CDH4 mRNA expression in lung cancer tissue
Variable N CDH4 mRNA P
Median (mean, range)
Gender 0.137
Female 28 0.088(0.190, 0.019–1.367)
Male 114 0.075(0.141, 0.012–2.661)
Age 0.539
<65 99 0.080(0.167, 0.013–2.661)






Squamous 77 0.067(0.116, 0.012–1.367)
Adenocarcinoma 58 0.125(0.203, 0.013–2.661)
Others 3 0.084(0.096, 0.081–0.125)
SCLC 4 0.108(0.106,0.069-0.139)
Lymph node metastasis 0.733
0 69 0.092(0.161, 0.012–1.367)
1 21 0.067(0.113, 0.013–0.408)
2–3 26 0.073(0.187, 0.016–2.661)
4–24 24 0.086(0.120, 0.020–0.517)
Censoring 2 0.100(0.100, 0.078–0.123)
Stage 0.580
I–II 96 0.082(0.172, 0.012–2.661)
III–IV 46 0.079(0.106, 0.020–0.517)
Family history 0.404
Yes 25 0.070(0.115, 0.012–0.666)
No 105 0.083(0.167, 0.013–2.661)
Censoring 12 0.070(0.085, 0.040–0.172)
Smoking state 0.476
Yes 100 0.083(0.149,0.012-2.661)
No 31 0.080(0.180, 0.019–1.367)
Censoring 11 0.072(0.088, 0.040–0.172)
Drinking state 0.216
Yes 73 0.068(0.164, 0.013–2.661)
No 58 0.090(0.146, 0.012–1.367)
Censoring 11 0.072(0.088, 0.040–0.172)
*A p value ≤0.05 was considered statistically significant
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Results
Correlation of CDH4 mRNA expression with clinical
parameters of lung cancer patients
No correlation was identified between CDH4 mRNA
expression and gender, age, lymphnode metastasis,
TNM stage, family history, smoking state, drinking
state (P > 0.05), but grade and histotype (P < 0.05)
(Table 1). CDH4 mRNA expressed higher in “middle-
low”–“low” grade compared with “high”–“middle” grade.
In adenocarcinoma, SCLC, other histotypes, and
squamous lung cancer, the CDH4 mRNA expression was
dropped off.
CDH4 mRNA expression in lung cancer tissues and
normal tissues
CDH4 mRNA relative value was widely distributed
among these tested patients. In the group of tumor
tissues, the CDH4 mRNA relative value ranged
between 0.01 and 2.66 (median 0.08), whereas in the
groups of normal tissues, it ranged between 0.03 and
3.01 (median 0.26). The relative value of CDH4
mRNA in lung cancer tumor tissues (mean 0.15) was
lower than those of normal tissues (mean 0.32, P <
0.05) (Table 2).
Discussion
In our research, we first conducted RT-PCR examin-
ing CDH4 mRNA expression in 142 paired cases of
lung cancer tissues and noncancerous tissues. We
found that CDH4 mRNA expression was not
associated with gender, age, lymph node metastasis,
TNM stage, family history, smoking state, drinking
state, but histotype and grade. CDH4 mRNA was
expressed higher in “middle-low”–“low” grade com-
pared with “high”–“middle” grade. In adenocarcin-
oma, SCLC, other histotypes, and squamous lung
cancer, the CDH4 mRNA expression was dropped
off. It suggested that CDH4 might play an important
role in tissue differentiation. This was consisted with
the precious studies [15–17]. In Duguay et al.s’
experiment, the expression levels of cadherins were
different in fibroblasts. It suggested that we could
sort cell by different levels of cadherins cell surface
expression as well as subtype [15]. What is the most,
we found that CDH4 mRNA expression was signifi-
cantly downregulated in lung tumors compared with
normal tissues. In some cancers, for example,
leiomyoma and ovarian carcinoma, CDH4 was
treated as proto-oncogene, CDH4 gene expression
was upregulated [18]. However, in some other
cancers, such as nasopharyngeal carcinoma, gastric
cancer, and colorectal cancer, CDH4 acted as anti-
oncogene, CDH4 gene expression was downregu-
lated[11, 12]. In lung cancer, our study suggested
that CDH4 might serve as tumor surpressor gene,
though more research need to be conducted.
Conclusions
In conclusion, our study first reported that the expres-
sion levels of CDH4 mRNA were decreased in the lung
cancer tissues. CDH4 might be a tumor suppressor gene
in lung cancer. But further studies will be necessary to
confirm this result.
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Table 2 The nonparametric tests of CDH4 mRNA expression in
lung tumor tissues
Median (mean, range) P value
Normal 0.26(0.32, 0.03–3.01) <0.001
Cancer 0.08(0.15, 0.01–2.66)
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